Tumor-induced osteomalacia (TIO) is a disorder that depletes the body of phosphorus and can result in weak bones.
For adults and children with TIO caused by tumors that cannot be found or completely removed, CRYSVITA may help the body retain a normal amount of phosphorus.
CRYSVITA is the first and only FDA-approved therapy to target the underlying cause of chronic hypophosphatemia in TIO.
Ask your doctor if CRYSVITA may be right for you.
UltraCare® Patient Services for CRYSVITA is a program that provides information about how to access CRYSVITA.
Our services are designed to help you understand your insurance coverage and tell you if you are eligible for financial and patient assistance programs that can help make CRYSVITA affordable.
Please note a completed Start Form is required for enrollment.
Visit UltraCare for CRYSVITA
